ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year

editorial-team@simplywallst.com (Simply Wall St)

Wed, Mar 26, 2025, 6:16 AM 3 min read

The latest analyst coverage could presage a bad day for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon. Surprisingly the share price has been buoyant, rising 14% to US$13.15 in the past 7 days. Whether the downgrade will have a negative impact on demand for shares is yet to be seen.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Following the latest downgrade, the current consensus, from the six analysts covering ARS Pharmaceuticals, is for revenues of US$83m in 2025, which would reflect a perceptible 6.8% reduction in ARS Pharmaceuticals’ sales over the past 12 months. After this downgrade, the company is anticipated to report a loss of US$1.36 in 2025, a sharp decline from a profit over the last year. However, before this estimates update, the consensus had been expecting revenues of US$125m and US$0.36 per share in losses. So there’s been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

See our latest analysis for ARS Pharmaceuticals

There was no major change to the consensus price target of US$29.50, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 6.8% by the end of 2025. This indicates a significant reduction from annual growth of 126% over the last three years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 20% annually for the foreseeable future. It’s pretty clear that ARS Pharmaceuticals’ revenues are expected to perform substantially worse than the wider industry.

The most important thing to take away is that analysts increased their loss per share estimates for this year. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We’re also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn’t blame investors for being more cautious on ARS Pharmaceuticals after the downgrade.